Asset profile
ICP-488
Small molecule
Evidence outlook · registrational
Psoriasis: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2026-05) has passed without a status update. Check News for topline announcements.
NCT06109818: The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.
Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
70 competitors in this universe: 10 direct rivals (same mechanism and indication), 2 same-class, 58 same-indication; 26 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| ICP-488: this drug | Phase 3 | Small molecule | TYK2 | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Envudeucitinib | Phase 3 | Small molecule | TYK2 | ||
| HS-10374 | Phase 3 | Small molecule | TYK2 | ||
| SYHX1901 | Phase 3 | Small molecule | TYK2 | ||
| TQH3906 | Phase 3 | Small molecule | TYK2 | ||
| WD-890 | Phase 3 | Small molecule | TYK2 | ||
| Zasocitinib | Phase 3 | Small molecule | TYK2 | ||
| CMS-D001 | Phase 2/3 | Small molecule | TYK2 | ||
| BMS-986322 | Phase 2 | Small molecule | TYK2 | ||
| CS32582 | Phase 1/2 | Small molecule | TYK2 | ||
| D-2570 | Phase 3 | Small molecule | TYK2 | ||
| GLPG3667 | Phase 2 | Small molecule | TYK2 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F |
…and 55 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.